Our Pipeline
Our Pipeline
We are targeting urgent unmet patient needs with our innovative approach.
Dectin-2
- Triple-Negative Breast Cancer
- Clear Cell Renal Cell Carcinoma
- Head & Neck Cancer
- Ovarian Cancer
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Melanoma
Phase 1
Funds 3 bispecific Boltbody ISACs through early clinical development
Funds 1 Boltbody ISAC through early clinical development
BDC-3042
BDC-3042 is a first-in-class antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells. We identified monoclonal antibodies that are capable of binding to and agonizing Dectin-2, a cell surface protein on tumor-supportive macrophages. The activation of these macrophages results in the production of pro-inflammatory cytokines, consistent with the characteristics of tumor-destructive macrophages. Dectin-2 has the potential to reprogram tumor-supportive macrophages into tumor-destructive macrophages to elicit a productive anti-tumor immune response.
BDC-4182
BDC-4182 is Bolt’s next-generation ISAC candidate targeting Claudin 18.2, a novel target in oncology, with programs in development for the treatment of gastric or gastroesophageal junction cancer and pancreatic cancer.